Gut microbiota and low-dose IL-2 therapy, Paris, France
70 fecal samples from adults in Paris, France, including some with autoimmune/inflammatory disease or Crohn's disease, in an intervention study of low-dose interleukin-2 drug therapy effects on gut microbiota. machine-written summary
12 samples · 70 runs · FR · Adult · 2022 · 22.2 Mbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 132 sample values (collection date, country, health condition, health condition detail, intervention, intervention detail, latitude, location locality) |
| ○ Abstract / description | read; no usable statement |
| ○ Full text | read; no usable statement or table · PMC9536277 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention · arms resolved
6 people have samples in more than one arm.
Non-antibiotic pharmaceutical given as the study intervention (metformin design non_randomized_controlled · population autoimmune_inflammatory · Low-dose IL-2 treatment; FMT from IL-2LD-treated donors to naive mice
“Low-dose IL-2 (IL-2LD) stimulates Tregs” — abstract:35917175 (study level; per-sample arms are in the intervention column below)
longitudinal — not resolved
6 of 6 people sampled more than once (12 samples; median 2, up to 2 per person).
No Sandpiper profile for this project's samples yet.
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 12 | 100% | ||||
| country | 12 | 100% | 12 | |||
| health_condition | 12 | 100% | 12 | |||
| subject_id | 12 | 100% | 12 | |||
| collection_date | 12 | 100% | 12 | |||
| detailed_location | 12 | 100% | ||||
| health_condition_detail | 12 | 100% | 12 | |||
| intervention | 12 | 100% | 12 | |||
| intervention_detail | 12 | 100% | 12 | |||
| latitude | 12 | 100% | 12 | |||
| location_locality | 12 | 100% | 12 | |||
| location_region | 12 | 100% | 12 | |||
| longitude | 12 | 100% | 12 |
- Low-dose IL-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation. 2022 PMID 35917175 PMC9536277 own_data
Archive description
Gut microbiota (GM) dysbiosis is associated with inflammatory bowel diseases and also with cardiometabolic, neurologic, and autoimmune diseases. GM composition has a direct effect on the immune system, and vice versa, and particularly on regulatory T cell (Treg) homeostasis. Low-dose interleukin-2 (IL-2LD) stimulates Tregs and is a promising treatment for autoimmune and inflammatory diseases. We aimed to evaluate the impacts of IL-2LD on GM, and correlatively on the immune system. We used 16S ribosomal RNA profiling and metagenomics to characterise GM of mice and humans treated or not with IL-2LD. We performed fecal microbiota transplantation (FMT) from IL-2LD-treated to naive recipient mice and evaluated its effects in models of type-1 diabetes and gut inflammation. IL-2LD markedly affects GM composition in mice and humans. Transfer of an IL-2-tuned microbiota by FMT prevented type 1 diabetes in NOD mice and protected C57BL/6J mice from dextran sulfate sodium-induced colitis. Metagenomic analyses highlighted a role for several species impacted by IL-2LD and for gut microbial pathways involved in the biosynthesis of amino acids, short-chain fatty acids, and L-arginine. Our results demonstrate that IL-2LD induces changes in GM that are involved in the therapeutic effects of IL-2LD and suggest cross-talk between Tregs and GM. These results provide novel perspectives for understanding the mode of action of Treg-directed therapies.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.title · “shapes a tolerogenic gut microbiota that improves”
- body site study.description · “Gut microbiota (GM) dysbiosis”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN27749350 | collection_date | 2019-03-01 | R1 | 0.90 | biosample.attribute:collection_date | 2019-03-01 |
| SAMN27749350 | country | FR | R1 | 0.90 | sample.attr.geo_loc_name | France: Paris |
| SAMN27749350 | health_condition | autoimmune_inflammatory | R1 | 0.90 | biosample_attr | Behcet |
| SAMN27749350 | health_condition_detail | Behcet | R1 | 0.90 | sample.attr.background_disease | Behcet |
| SAMN27749350 | intervention | no_intervention | R1 | 0.80 | biosample.attribute:treatment | treatment: beforeIL2 |
| SAMN27749350 | intervention_detail | before low-dose IL-2 treatment | R1 | 0.80 | biosample.attribute:treatment | treatment: beforeIL2 |
| SAMN27749350 | latitude | 48.8566 | R1 | 0.90 | biosample.attribute:lat_lon | 48.8566 N 2.3522 E |
| SAMN27749350 | location_locality | Paris | R1 | 0.85 | biosample.attribute:geo_loc_name | France: Paris |
| SAMN27749350 | location_region | Ile-de-France | R1 | 0.60 | biosample.attribute:lat_lon | 48.8566 N 2.3522 E |
| SAMN27749350 | longitude | 2.3522 | R1 | 0.90 | biosample.attribute:lat_lon | 48.8566 N 2.3522 E |
| SAMN27749350 | subject_id | patient1 | R1 | 0.70 | sample.name_rule:alias | meta_Behcet_beforeIL2_patient1 |
Sequencing
70 runs over 12 samples · mean 1.29 Gbp per run (median 22.2 Mbp, total 90.28 Gbp; 70 runs with a base count) · layout PAIRED 42, SINGLE 28 · platform ILLUMINA 42, ION_TORRENT 28 · models Illumina MiSeq (42), Ion Torrent Proton (28) · 0% of runs with a Sandpiper profile · first public 2022-08-22 – 2022-08-28
Authors (15)
Tchitchek N first · Nguekap Tchoumba O · Pires G · Dandou S · Campagne J · Churlaud G · Fourcade G · Hoffmann TW · Strozzi F · Gaal C · Bonny C · Le Chatelier E · Erlich SD · Sokol H · Klatzmann D last
Downloads
PRJNA831236.csv.gz (1.3 KB) · parquet (71.0 KB) — all 12 samples, every field with route and confidence · PRJNA831236_determinations.csv.gz (1.9 KB) — 132 evidence rows